On August 28, 2018 Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing a patient-specific T-cell product designed to be delivered following a haploidentical hematopoietic stem cell transplant, or HSCT, in order to support the patient’s newly transplanted immune system before it becomes fully functional, reported that it is scheduled to attend the following investor conferences in September 2018 (Press release, Kiadis, AUG 28, 2018, View Source [SID1234529092]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Goldman Sachs 8th Annual Biotech Symposium
September 7, 2018, Goldman Sachs Offices, River Court, 120 Fleet Street, London, UK
Oppenheimer Fall Summit focused on Specialty Pharma and Rare Disease
September 26-27, 2018, The Langham, 400 5th Avenue, New York, USA
KBC Securities 6th Biotech and Healthcare Conference
September 27, 2018, Convene Grand Central, 101 Park Avenue, New York, USA
For more information, please contact:
Kiadis Pharma:
Karl Hård, Head of IR & Communications
Tel. +31 611 096 298
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 714 1787